A Phase 1 interventional study of ABP-671 plus allopurinol in Gout Chronic, Gout and DDI (Drug-Drug Interaction), sponsored by Atom Therapeutics Co., Ltd. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Atom Therapeutics Co., Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing allopurinol in Gout — 1 open to participants now, 1 under way, none of them phase 3. Allopurinol · Gout.
Among the 16 studies testing allopurinol in Gout, this one is the 14th largest by enrollment, is the only one that started in 2026, is one of 2 in phase 1, and was the 16th registered.
345 studies on the registry are indexed under Gout; 49 are open to participants now.
Browse Gout studies →1 of the 16 studies testing allopurinol in Gout is open now. Recruiting first, the newest first:
Haiphong University of Medicine and Pharmacy
Healthy volunteers
Allopurinol: first FDA approval 1966 (ZYLOPRIM), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 4 5
First in 1998; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 83 across 286 interventional studies indexed under Gout.
Median enrollment 46 across the 16 interventional studies. Of the 13 that completed or were terminated, 6 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 16 have an industry lead sponsor. The 10 most frequent:
Atom Therapeutics Co., Ltd is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Atom Therapeutics Co., Ltd has 5 studies filed under Gout — fewer than ten, so there is no comparison to draw.
1 of the studies testing allopurinol in Gout that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07369622Haiphong University of Medicine and PharmacyHLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness | 2027-06-20 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing allopurinol in Gout, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ABP-671 plus allopurinol
Drug pages: ABP-671 · Allopurinol
All subjects undergo three sequential 7-day periods: Period 1 (Day 1-7): Allopurinol； Period 2 (Day 1-7): Allopurinol Plus ABP-671； Period 3 (Day 1-7): ABP-671；
Maximum plasma concentration (Cmax) of allopurinol
Maximum observed plasma concentration (Cmax) of allopurinol following administration of allopurinol alone and in combination with ABP-671 at steady state.
Time frame: Base line, through Day1, Day 7,Day8,D14,D15,D21
Area under the plasma concentration-time curve over the dosing interval (AUC) of allopurinol
Area under the plasma concentration-time curve over the dosing interval (AUC) of allopurinol following administration of allopurinol alone and in combination with ABP-671 at steady state.
Time frame: Base line, through Day1, Day 7,Day8,D14,D15,D21
Maximum plasma concentration (Cmax) of ABP-671
Maximum observed plasma concentration (Cmax) of ABP-671 when administered with allopurinol and following a post-combination ABP-671 alone period.
Time frame: Though Day7,Day8,Day14,Day15,Day21
Area under the plasma concentration-time curve over the dosing interval (AUC) of ABP-671
Area under the plasma concentration-time curve over the dosing interval (AUC) of ABP-671 when administered with allopurinol and following a post-combination ABP-671 alone period.
Time frame: Though Day7,Day8,Day14,Day15,Day21
Incidence of treatment-emergent adverse events (TEAEs)
Number and percentage of participants experiencing treatment-emergent adverse events.
Time frame: Through study completion, an average of 51 days
Plan to share: No — there is no need at present.
No publications or documents are linked to this record.
Ran from Jan 2026 to primary completion in Aug 2026, 6 months.
Of 37 industry-sponsored phase 1 interventional studies under Gout, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's 6 months is close to that.
Counting every sponsor, half of 40 studies reached it within 6 months; a quarter within 1 and three quarters within 14.
Primary completion moved once since we started tracking on Sep 25, 2026: Jul 2026 → Aug 2026, on Nov 2, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: ABP-671 · Allopurinol
Atom Therapeutics Co., Ltd